Ascendis Pharma A/S, a biopharmaceutical firm, is dedicated to addressing the medical community's unmet needs. Its leading treatment SKYTROFA is geared towards patients suffering from growth hormone deficiency (GHD). Ascendis Pharma is also advancing TransCon Growth Hormone to target pediatric GHD, adult GHD, and Turner syndrome; TransCon Parathyroid Hormone for treating hypoparathyroidism in adults; and TransCon C-type natriuretic peptide to combat achondroplasia. The organisation is making strides in the development of TransCon toll like receptors 7/8 agonist for intratumoral delivery and TransCon IL-2 ß/? for systemic delivery. Founded in 2006, the Denmark-based biopharmaceutical company has its headquarters in Hellerup.